Professional
Added to YB: 2026-02-05
Pitch date: 2026-02-03
EXPRS2.ST [bullish]
ExpreS2ion Biotech Holding AB (publ)
-11.56%
current return
Author Info
We perform researched powered investment banking with a belief that Scandinavia will be a hotspot for the major future innovations within tech and lifescience. Visit their website.
Company Info
ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally.
Market Cap
SEK 51.0M
Pitch Price
SEK 17.30
Price Target
44.00 (+188%)
Dividend
N/A
EV/EBITDA
-0.30
P/E
-0.82
EV/Sales
1.44
Sector
Biotechnology
Category
growth
ExpreS2ion Biotech: A polyclonal plot twist
EXPRS2.ST: Novel HER2 vaccine ES2B-C001 in Phase I showing early immunogenicity; targets multibillion-dollar market with polyclonal approach vs single-epitope mAbs; phase III-validated ExpreS2 platform de-risks tech; estimated $2.2bn peak sales by 2044e but 9% LoA limits upside. Needs funding for Phase II, faces patent expiry 2029-2032. Redeye price target SEK44 vs SEK14 current.
Read full article (64 min)